Objective: Our team developed an attention control condition, called the Brain Health Group (BHG), for a randomized controlled trial (RCT; NCT03594734). The focus of the BHG was on brain health education and self-management. The objectives of this supplementary analysis are to (1) Describe compliance with the 12-month BHG; (2) Examine efficacy for improving general self-efficacy (GSE, primary) and secondary outcomes; and (3) Describe findings from the program evaluation.
Design: English-speaking adults (18-64 years old) who were ≥6 months post a moderate-to-severe TBI were randomized to the BHG ( = 29) or active intervention ( = 28). Data were collected at baseline and 12 months, including GSE, depression, satisfaction with life (SWL), self-rated abilities for health practices (SRAHP), and alcohol use. Program evaluation was conducted at 12 months.
Results: Attendance was 89%, and goal tracking was 63%. Within group analysis showed a significant increase in SRAHP scores ( = 0.018). Non-significant increases in GSE and SWL were observed, and participants perceived the BHG as helpful. No significant changes in depression or alcohol use were reported.
Conclusion: People with TBI can engage in and benefit from the BHG and perceive the program as helpful for improving knowledge about brain health and awareness of self-management skills.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/02699052.2023.2225874 | DOI Listing |
Neurology
September 2011
Banner Alzheimer's Institute, 901 E Willetta Street, Phoenix, AZ 85006, USA.
Arch Gen Psychiatry
August 2011
Banner Alzheimer's Institute, 901 E Willetta St., Phoenix, AZ 85006, USA.
Arch Neurol
October 2011
Division of Epidemiology, University of California, Berkeley, 94720-3190, USA.
Objective: To delineate the trajectories of Aβ42 level in cerebrospinal fluid (CSF), fludeoxyglucose F18 (FDG) uptake using positron emission tomography, and hippocampal volume using magnetic resonance imaging and their relative associations with cognitive change at different stages in aging and Alzheimer disease (AD).
Design: Cohort study.
Setting: The 59 study sites for the Alzheimer's Disease Neuroimaging Initiative.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!